Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Regor Pharmaceuticals (USA) ("Regor") has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors ...
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK …
WEB9 hours ago · Regor’s most advanced orally-administered CDK4/2 inhibitor in the clinic, RGT-419B, will be added to Roche’s pipeline. RGT-419B is a potent CDK4 inhibitor with increased activity on CDK2 ...
Genentech buys Regor’s CDK inhibitors in $850m deal - Yahoo …
WEB7 hours ago · Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer cyclin-dependent kinase (CDK) inhibitors in an $850m deal. The deal, anticipated ...
Genentech inks $850M upfront deal for Regor's CDK inhibitors
WEB1 day ago · Roche Genentech Regor Therapeutics mergers and acquisitions. Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer ...
Roche turns to a startup in search for new breast cancer drugs
WEB2 days ago · Roche on Monday agreed to pay $850 million to acquire two experimental breast cancer drugs being developed by China-based biotechnology startup Regor Therapeutics. The deal hands Roche two medicines that Regor, in a statement, described as “next-generation” versions of the CDK inhibitors widely used to …
Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for …
WEB1 day ago · Sep 30, 2024 5:44am. By Ian Walker. Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment ...
Genentech buys Regor’s CDK inhibitors in $850m deal
WEB8 hours ago · Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer cyclin-dependent kinase (CDK) inhibitors in an $850m deal. The deal, anticipated to close in Q4 2024, was unveiled by Genentech’s parent company Roche at its pharma day in London. The pharmaceutical giant also shared that it is ...
Genentech buys Regor's next-gen CDK inhibitors for $850M
WEB1 day ago · Regor Therapeutics Group agrees to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash payment of $850 million.
Regor Enters into a Definitive Purchase Agreement for ... - BioSpace
WEB1 day ago · CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- Regor Pharmaceuticals (USA) (“Regor”) has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors from Regor for the treatment of breast cancer.
Genentech To Acquire Portfolio Of Next-generation CDK Inhibitors …
WEB1 day ago · (RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK ...
- Some results have been removed